RESEARCHER PROFILE (Filmed May 2024)
Dr Shelley Keating AES AEP ESSAM
Senior Lecturer, Clinical Exercise Physiology and Accredited Exercise Physiologist
School of Human Movement and Nutrition Sciences
The University of Queensland
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
Dr Keating has an established research profile that is delivering impact for patients and clinicians. Her research has led to the development of safe and feasible exercise programs that generate significant improvement in the cardiometabolic health of individuals with MASLD and related chronic disease. Drawing on these findings, Dr Keating has developed national and international exercise guidelines for MASLD. Her research has led to a paradigm shift in how exercise is prioritised in MASLD management and has been adopted into exercise prescription recommendations in 15 international guidelines for MASLD management across 12 countries.
Dr Keating’s research had found a lack of awareness, uptake, and sustainability of exercise for MASLD management. Her ongoing program of research is informed by, and co-designed with, people with MASLD and related chronic disease, to find sustainable exercise solutions.
Her contribution to the field was recognised by the prestigious 2020 Australia and New Zealand Obesity Society Young Investigator award. Shelley has been an ESSA (Exercise & Sports Science Australia) member since 2007 and has 16 years of clinical AEP experience in people with cardiometabolic disease including MAFLD.
Her mission is to change the way that exercise is prioritised, accessed, and delivered to improve the health and wellbeing of people with MASLD and related type 2 diabetes.
Source: Supplied & ESSA (Exercise & Sports Science Australia)
Note: AES is the acronym for Accredited Exercise Scientist (AES), AEP is the acronym for Accredited Exercise Physiologist, ESSAM is the acronym for Exercise & Sports Science Australia Member.
-
Impact of NextSense Institute Research in the field of sensory disabilities
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
-
Biomarkers for early sepsis detection
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
-
Investigating invasive lobular carcinoma and metaplastic breast cancer sub-types
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
